Studies in pancreatic cancer have revealed that MUC1 in both cancer cells and exosomes presents specific dynamic epitopes identifiable by the anti-MUC1 antibody SN-131, which binds distinctively to core 1 type O-glycans on MUC1, as opposed to core 2 types in normal cells, demonstrating the therapeutic potential of targeting these unique O-glycosylation areas on MUC1 in pancreatic cancer cells (152). This evidence concerns the gene MUC1 and pancreatic neoplasm.